7,8-Cyclicmorphinan Analogs for Selective Peripheral Opioid Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analgesics targeting opioid receptors often produce undesirable central side-effects and fail to effectively manage chronic pain, particularly neuropathic and inflammatory pain, due to their inability to selectively act on peripheral opioid receptors.
Innovation Solution
Development of novel 7,8-cyclicmorphinan analogs and pharmaceutical compositions that modulate µ, δ, κ, and ORL-1 opioid receptors, allowing for selective action on both central and peripheral sites to provide analgesia with reduced central side-effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If centrally penetrating κ agonists are used to produce antinociceptive effects, then analgesic efficacy is improved, but undesirable central side-effects such as sedative and psychotomimetic effects occur
Solution Approach 1:
The patent divides the opioid receptor system into peripheral and central components, designing compounds that selectively target peripheral κ-opioid receptors while minimizing penetration into the central nervous system. This spatial segmentation allows the drug to produce analgesic effects at peripheral sites without activating central receptors that mediate side-effects.
Solution Approach 2:
The invention creates compounds with differentiated distribution properties - high concentration at peripheral opioid receptors where analgesia is needed, and low concentration in the central nervous system where side-effects occur. This local quality differentiation is achieved through molecular structure optimization that limits blood-brain barrier penetration while maintaining peripheral receptor affinity.
2Reliability
If non-selective opioid receptor ligands are used to achieve broad analgesic coverage, then analgesic efficacy is improved, but selectivity for specific receptor subtypes is reduced
Solution Approach 1:
The patent employs systematic modification of molecular parameters including substituent groups, ring structures, and stereochemistry to optimize the balance between analgesic efficacy and receptor selectivity. By adjusting these chemical parameters, the compounds achieve enhanced affinity for κ-opioid receptors while maintaining appropriate selectivity profiles across different opioid receptor subtypes.
Data Source
AI summary
The application is directed to compounds of Formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein Cy, R1-R3, R4A, and R4B are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.